Can-Fite BioPharma Ltd. (CANF) is an innovative, clinical-stage biopharmaceutical company headquartered in Petach Tikva, Israel. The company is traded publicly on the New York Stock Exchange under the ticker "CANF". Founded in 1994, Can-Fite predominantly focuses on developing novel, small molecule drugs for the treatment of cancer, liver, inflammatory diseases, and sexual dysfunction.
The company adopts a patient-oriented approach, making a significant contribution to the advancement of healthcare by providing solutions to improve the lives of countless people worldwide. Their strong pipeline consists of several drugs in various stages of clinical development, leveraging their proprietary technology platform which is based on discoveries of specific biological pathways.
Can-Fite BioPharma's flagship product, Piclidenoson (CF101), is currently in Phase III trials for treating rheumatoid arthritis and psoriasis. The drug has shown promising preliminary results, demonstrating efficacy in reducing symptoms with a good safety profile. Another product in their pipeline, Namodenoson (CF102), is in Phase II clinical trials for hepatocellular carcinoma and non-alcoholic steatohepatitis (NASH). Namodenoson has received Orphan Drug Designation from the U.S Food and Drug Administration (FDA) and European Medicines Agency (EMA). The company is also testing CF602, its preclinical drug candidate aimed at treating sexual dysfunction.
Can-Fite BioPharma is continuously researching and exploring novel treatment options in its quest to fill the therapeutic gaps in various disease areas with high unmet needs. The company works in collaboration with renowned scientific and academic institutions to undertake advanced preclinical and clinical research.
Furthermore, Can-Fite BioPharma has entered into partnership agreements with several major pharmaceutical companies worldwide to develop and commercialize its drug candidates. These collaborations have significantly driven its business growth while providing a path towards successful drug development.
Despite the inherent risks and uncertainties associated with drug development and commercialization, Can-Fite BioPharma is poised to deliver innovative therapies. The company's commitment to excellence in research and patient care, coupled with its robust pipeline, positions it well in the biopharmaceutical industry.
Can-Fite BioPharma operates under stringent ethical norms and rigorous scientific standards. Furthermore, it is committed to sustainability and responsible business practices, thereby contributing to the development of a healthier and more equitable society. In a nutshell, Can-Fite BioPharma is a dynamic company that enriches lives through its groundbreaking research and innovative therapeutics.